Advances in bispecific antibody therapy for relapsed/refractory multiple myeloma
Multiple myeloma is a hematologic malignancy originating from bone marrow plasma cells and remains incurable.Most patients eventually develop into relapsed/refractory multiple myeloma.Bispecific antibody therapy is a promising immunotherapeutic approach that has initially demonstrated significant efficacy.This article will review research progress of bispecific antibody in treatment of relapsed/refractory multiple myeloma.
NETL
NSTL
万方数据
